# Zim Laboratories share price today (Zim Laboratories Ltd, NSE: ZIMLAB)

> Zim Laboratories share price today: ₹142.39 at the NSE close on 3 November 2026, up 93.8% in a year. Zim Laboratories (NSE: ZIMLAB) is worth ₹765 crore, trades at a P/E of 207.3 and has closed between ₹64.09 and ₹150.70 over the past 52 weeks. > Zim Laboratories Ltd's share price has risen faster than its earnings: +93.8% in a year, against −56.4% for earnings per share. ZIMLAB · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/zim-laboratories-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹142.39 (+93.8% in a year)
- P/E: 207.3× (higher than 100% of the last 7.9 years)
- Revenue (Jun 2026): ₹94.2 Cr (+31.2% on a year ago)
- Profit (Jun 2026): −₹4.0 Cr
- Operating margin: 2.6% (−3.3 points on a year ago)
- ROCE: 5%, FY26
- ROIC: 1.5%, against a 12.0% cost of capital: −10.5 points

The main question: the share price moved +93.8% in a year while yearly earnings per share moved −56.4%. The difference came from the market paying a higher multiple. ## What is the Zim Laboratories share price today? Zim Laboratories Ltd's share price was ₹142.39 at the close on 3 November 2026. It has been rising for 24 weeks. That is 28.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹64 and ₹151, and at that close it sat 90% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 13 weeks in a row. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Zim Laboratories this quarter? One change stood out: lowest operating margin in 15 quarters. 1. Lowest operating margin in 15 quarters Operating margin was 2.6% in the June 2026 quarter, against 5.9% a year earlier. Why: The operating margin fell because staff costs, utility, fuel and power bills, and EU remediation consulting cost more. One-time TGA audit, European consulting, EU-GMP repairs and MIDC charges also weighed on it. Next results: check whether those one-time costs drop out next quarter. From the earnings call on 7 Aug 2026. ## What are Zim Laboratories' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Zim Laboratories reported revenue of ₹94.2 crore, up 31.2% from ₹71.8 crore a year earlier, and a loss of ₹4.02 crore. ### Zim Laboratories results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹94.2 crore | ₹71.8 crore | +31.2% |
| Profit | loss of ₹4.02 crore | loss of ₹1.87 crore | n/a |
| Earnings per share | ₹−0.75 | ₹−0.38 | n/a |
| Operating margin | 2.6% | 5.9% | −3.3 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Zim Laboratories' management discussed these results on a call held on 7 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Zim Laboratories share price history? Zim Laboratories closed at ₹142.39 on 3 November 2026, up 93.8% from ₹73.46 a year earlier (31 October 2025) and up 234.5% over five years. Its highest weekly close since September 2018 was ₹150.70 on 9 October 2026. ### Zim Laboratories share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹126.60 | +12.5% |
| 1 month ago · 1 Oct 2026 | ₹136.45 | +4.4% |
| 6 months ago · 30 Apr 2026 | ₹88.02 | +61.8% |
| 1 year ago · 31 Oct 2025 | ₹73.46 | +93.8% |
| 3 years ago · 3 Nov 2023 | ₹124.20 | +14.6% |
| 5 years ago · 4 Nov 2021 | ₹42.57 | +234.5% |
| Earliest weekly close in our records · 14 Sep 2018 | ₹62.14 | +129.1% |
| Highest weekly close since September 2018, also the 52-week high · 9 Oct 2026 | ₹150.70 | −5.5% |
| Lowest weekly close since September 2018 · 27 Mar 2020 | ₹17.03 | +736.1% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹64.09 | +122.2% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (433 weekly closes from 14 September 2018 to 3 November 2026.)

## What is the latest news on Zim Laboratories? 3 Nov 2026: Zim Laboratories closed at ₹142.39, up 12.5% on the week and up 4.4% on the month. 7 Aug 2026: Zim Laboratories held its results call for April to June 2026. Management guided: Final EU GMP report hoped for within 1-2 weeks; CAPA submission ready immediately after receipt. ### Earlier

- Results for April to June 2026: Revenue up 31.2% on a year earlier. ## What dividend does Zim Laboratories pay? Zim Laboratories has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. Not in its latest year. Zim Laboratories Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 4 of its last 12 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Zim Laboratories management say on the latest results call? On the call for April to June 2026, held on 7 August 2026, Zim Laboratories' management guided: Final EU GMP report hoped for within 1-2 weeks; CAPA submission ready immediately after receipt. > “It is now only a question of timing. Hopefully, it will come soon enough, and then we can start generating revenues from the EU business.”
> Zulfikar Kamal, on the call for April to June 2026

### What management guided

- EU supplies expected to start in Q4 if approval arrives in August; 8-10 product MAs expected after approval. - FY27 revenue growth of 10-15% even if EU approval slips to FY28. - FY28 revenue growth of 30-35% if EU approval and supplies start; 60-70% of growth attributed to EU. - Gross margin around 55-58% from product mix; post-EU operating margin described as upper-teens then mid-teens; delayed-EU FY27 margins similar to prior year; Q1 one-time items not recurring next quarter. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/7185/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 7 August 2026.)

## What to watch in Zim Laboratories' next results? When Zim Laboratories reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Final EU-GMP report and CAPA acceptance - check whether the no-critical-observation path converts into formal recertification. - What to check (from the call)
- Final EU-GMP report and CAPA acceptance - check whether the no-critical-observation path converts into formal recertification. - Australian TGA certificate and first product supplies - check whether CAPA review converts the existing order into commercial supplies. - EU registrations and first regulated-market supplies - check whether clearance translates into commercialization rather than further procedural delay. - Operating profit recovery and cash conversion - check one-off cost roll-off, debtor collections and inventory discipline. ## Which stock lists is Zim Laboratories on? Zim Laboratories is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market cap cr: 722.847384254164](https://www.sectoralpha.in/momentum-stocks-india)
- [Pharma stocks Market value (₹ crore): 722.847384254164](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Zim Laboratories profitable? Zim Laboratories Ltd posted a net loss of ₹4.0 Cr in the Jun 2026 quarter. Full-year FY26 profit was ₹6.0 Cr. Over 10 years profit has grown 1.8% a year on average. That loss is 4.3% of the quarter's revenue. The same quarter a year earlier lost ₹1.9 Cr. 3 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹6.0 Cr (−50.0% on the year before). On average over the last four quarters, profit changed −43.7% and revenue +9.3%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Zim Laboratories make, and is it growing? Zim Laboratories Ltd reported ₹94.2 Cr of revenue in the Jun 2026 quarter, +31.2% on the same quarter a year earlier. Over 10 years it has grown 3.4% a year on average. The last full year, FY26, came in at ₹374 Cr. The last four reported quarters add to ₹397 Cr. FY26 revenue was ₹374 Cr, −1.3% on the year before. Recent pace: the last four quarters grew +9.3% on average, against 3.4% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +7.6%, against +1.9% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −60.6%, against −54.6% a year (rolling over). ## How much of every ₹100 of sales does Zim Laboratories keep? Zim Laboratories Ltd's operating margin was 2.6% in the Jun 2026 quarter, 3.3 percentage points lower than the same quarter a year ago. Across 12 years it has been between −4.4% and 13.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −3.3 percentage points on the year while gross margin changed −0.1 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Zim Laboratories' profit turning into cash? Over the last 3 years, 306% of Zim Laboratories Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹50.0 Cr of operating cash against ₹6.0 Cr of profit. After ₹44.0 Cr of spending on assets, ₹6.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 306% of profit came in as cash: the cash cycle got 90 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 3.2× depreciation over three years. The next section checks what that spending is building. ## Where does Zim Laboratories' cash go? Zim Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 152 days in FY26, up from 62 days in FY21. It spent ₹178 Cr on assets over the last 3 years. Customers take 106 days to pay, and stock sits for 207 days on average. At FY26 sales of ₹374 Cr, each day of that cycle ties up about ₹1.0 Cr, so roughly ₹156 Cr is tied up in the business at any time. FY26: customers took 106 days to pay and stock sat for 207 days, about 6.8 months of sales sitting as stock, for a full cycle of 152 days, longer than FY21's 62. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 207 days. Customers pay about 106 days after that. Suppliers are paid at 161 days. Together that makes the 152-day cycle. Spending on assets: ₹178 Cr over the last 3 years, against ₹56.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹96.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Zim Laboratories' P/E ratio, and how does it compare with its own history? Zim Laboratories Ltd's P/E is 207.3×, about the highest it has ever been. Its usual P/E (the middle reading) is 28.3×, over 7.9 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹0.76. Why the multiple is where it is: over the past year earnings per share moved −56.4% while the price moved +93.8%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +27.3% a year; about −10.2% a year came from earnings growth and about +37.5 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Zim Laboratories business getting better or worse? Zim Laboratories Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −60.6% in the latest quarter, against −6.0% at its best in 12 quarters, with ROCE falling at 5.7%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Zim Laboratories earn on its capital? Zim Laboratories Ltd earned a ROCE of 5% in FY26. Its return on capital used (ROIC) is 10.5 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 1.6% net margin and 0.69× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 1.6% net margin × 0.69× asset turnover × 1.81× leverage (assets divided by equity) ≈ 2.0% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 1.5% − 12.0% = −10.5 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Zim Laboratories have too much debt? Zim Laboratories Ltd has total debt of ₹127 Cr against shareholder equity of ₹296 Cr as of Jun 2026, so its debt is 0.43× its equity. Year by year, that ratio went from 0.30 in FY22 to 0.43 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Zim Laboratories shareholding pattern? Promoters cut their stake in Zim Laboratories Ltd by 3.0 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 30.3% of the company. Domestic institutions moved +1.2 points over the same period, to 1.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −3.0 points over 8 quarters, to 30.3%; Domestic institutions: +1.2 points over 8 quarters, to 1.2%; Foreign institutions: +0.2 points over 8 quarters, to 0.2%. Why the owners changed: promoters drove it (−3.0 points), with the other side taken by domestic institutions (+1.2 points). They reduced their stake. ## How far is Zim Laboratories from balance-sheet trouble? For Zim Laboratories Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Zim Laboratories rank in its industry? 42.2 out of 100, rank 32 of 44 in Pharma - Formulators, with 71% of the evidence available. Zim Laboratories Ltd scores 42.2 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 32. Relative strength against the index is 47%, and revenue and profit growth are weak. The four parts add up to the total exactly: 10.1 + 5 + 8.6 + 18.5 = 42.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Zim Laboratories compared with? Zim Laboratories ranks 32 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 42.2 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. Zim Laboratories Ltd this page ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.1/35 · Revenue 7.5% · Profit -60.6% · Operating margin change -3.3 points · 65% evidence Capital efficiency 5.0/25 · ROCE 4.8% · Operating margin 2.6% · 100% evidence Valuation 8.6/20 · P/E 198× · PEG n/a · 15% evidence Relative strength 18.5/20 · Lead over its industry 21% · Lead over NIFTY 500 47% · 1 year 85.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 10.1 + 5 + 8.6 + 18.5 = 42.2 · What this means: Relative strength against the index is 47%, and revenue and profit growth are weak. 33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Zim Laboratories in size? Zim Laboratories is the 41st largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Bafna Pharmaceuticals, Bajaj Healthcare and Lincoln Pharmaceuticals. Just below it: Kilitch Drugs (India), Influx Healthtech and Syncom Healthcare. ### Pharma - Formulators companies close in size

1. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) ₹1,060 crore
2. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) ₹1,031 crore
3. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) ₹1,000 crore
4. Zim Laboratories Ltd ₹731 crore
5. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) ₹704 crore
6. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) ₹612 crore
7. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) ₹17 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Kanoria Chemicals & Industries Ltd](https://www.sectoralpha.in/stocks/kanoria-chemicals-industries-ltd) ₹731 crore · Chemicals - Organic - Alcohol Based
2. [Mukka Proteins Ltd](https://www.sectoralpha.in/stocks/mukka-proteins-ltd) ₹731 crore · FMCG Processing - Other
3. Zim Laboratories Ltd ₹731 crore
4. [Manba Finance Ltd](https://www.sectoralpha.in/stocks/manba-finance-ltd) ₹730 crore · NBFC - Others
5. [IIRM Holdings India Ltd](https://www.sectoralpha.in/stocks/iirm-holdings-india-ltd) ₹728 crore · Miscellaneous

## What else do people ask about Zim Laboratories? ### What is Zim Laboratories's share price today? Zim Laboratories Ltd's share price is ₹142.39, +93.8% over the past year. The whole company is worth ₹765 Cr on the market. In the last 52 weeks it traded between ₹64 to ₹151; today it is 90% of the way up from the low, 28.2% above its 200-day average (as of 3 November 2026). ### What were Zim Laboratories's latest quarterly results? Zim Laboratories Ltd reported revenue of ₹94.2 Cr and a net loss of ₹4.0 Cr for the Jun 2026 quarter. Earnings per share were −₹0.75. The operating margin was 2.6%, 3.3 percentage points lower than a year earlier (as of 3 November 2026). ### What is Zim Laboratories's market cap? Zim Laboratories Ltd's market capitalisation is ₹765 Cr at a share price of ₹142.39. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Zim Laboratories performing? Zim Laboratories Ltd's share price has been rising for 24 weeks. Over the past 13 weeks it has done better than the NIFTY 500, for 13 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Zim Laboratories's share price go up? This page does not forecast Zim Laboratories Ltd's share price. What it shows instead: the share price is ₹142.39, and it has been rising for 24 weeks. Its P/E of 207.3× is higher than 100% of its own last 8 years (as of 3 November 2026). ### Who owns Zim Laboratories? Promoters own 30.3% of Zim Laboratories Ltd, foreign institutions 0.2%, domestic institutions 1.2% and the public 68.3% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 3.0 percentage points over 8 quarters (as of 3 November 2026). ### Does Zim Laboratories have too much debt? Zim Laboratories Ltd has a moderate amount of debt: its debt is 0.43× its equity, and its operating profit is 2 times its interest bill. FY26 borrowings were ₹127 Cr against equity of ₹297 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Where is Zim Laboratories in its business cycle? Zim Laboratories Ltd's FY26 operating margin was 8.0%, against a 12-year range of −4.4% to 13.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 2.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Zim Laboratories story? The main question: the share price moved +93.8% in a year while yearly earnings per share moved −56.4%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Zim Laboratories a stock worth studying right now? What the numbers show: Zim Laboratories Ltd's share price has risen faster than its earnings: +93.8% in a year, against −56.4% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Zim Laboratories share price forecast for 2026? What management itself guided: Final EU GMP report hoped for within 1-2 weeks; CAPA submission ready immediately after receipt. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.